UroGen Pharma (URGN) Income from Continuing Operations: 2016-2025
Historic Income from Continuing Operations for UroGen Pharma (URGN) over the last 10 years, with Sep 2025 value amounting to -$33.3 million.
- UroGen Pharma's Income from Continuing Operations fell 40.87% to -$33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$164.6 million, marking a year-over-year decrease of 42.70%. This contributed to the annual value of -$126.9 million for FY2024, which is 24.09% down from last year.
- According to the latest figures from Q3 2025, UroGen Pharma's Income from Continuing Operations is -$33.3 million, which was up 33.23% from -$49.9 million recorded in Q2 2025.
- UroGen Pharma's 5-year Income from Continuing Operations high stood at -$21.9 million for Q3 2023, and its period low was -$49.9 million during Q2 2025.
- Over the past 3 years, UroGen Pharma's median Income from Continuing Operations value was -$32.3 million (recorded in 2024), while the average stood at -$32.4 million.
- As far as peak fluctuations go, UroGen Pharma's Income from Continuing Operations spiked by 30.62% in 2021, and later tumbled by 49.51% in 2025.
- Quarterly analysis of 5 years shows UroGen Pharma's Income from Continuing Operations stood at -$28.5 million in 2021, then fell by 1.47% to -$28.9 million in 2022, then climbed by 9.88% to -$26.0 million in 2023, then plummeted by 44.19% to -$37.5 million in 2024, then plummeted by 40.87% to -$33.3 million in 2025.
- Its Income from Continuing Operations was -$33.3 million in Q3 2025, compared to -$49.9 million in Q2 2025 and -$43.8 million in Q1 2025.